| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate |
2020-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2022548837-A |
| titleOfInvention |
Methods for Cancer Diagnosis, Prognosis, and Treatment |
| abstract |
Acquisition of the CD9 protein on the cell surface of NK cells confers an immunosuppressive phenotype on NK cells, making them less effective in immunotherapy. CD9 can be transferred from tumor cells to NK cells present in the tumor environment through the process of trogocytosis. A method of enhancing NK cell anti-tumor activity can include assessing NK receptor ligand expression within the tumor microenvironment for patients eligible for NK cell immunotherapy. |
| priorityDate |
2019-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |